FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for
Related Questions
How will the EU approval of twice-yearly Yeytuo® affect Gilead's stock valuation and price momentum?
What pricing and reimbursement assumptions should we model for Yeytuo® in European markets, and how does its cost compare to existing daily/monthly PrEP options?
What competitive pressure does Yeytuo® face from other long‑acting HIV‑1 PrEP candidates and biosimilars, and how might its uptake influence Gilead's market share in the HIV prevention space?